AVGO · Investment summary · as of 12 August 2026
Priced slightly ahead of what the business has demonstrated
Business type: Cyclical · mature and structurally stable
The operating path required by the price could not be established.
At $416.08, AVGO requires a 31% five-year revenue growth rate to justify its enterprise value — more than the business has ever demonstrated, at 19%.
The conditions that would settle the disagreement are dated to September 2026.
The value rests on an exit multiple of 24.2x, a terminal operating margin of 47% and a 13.0% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: A hyperscaler custom-XPU programme is cancelled, deferred or in-sourced during the FY2027 ramp.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | Prior memo's full State-A evidence re-verified against the same filings; no new filings since 29 July 2026 (submissions checked 12 August 2026: only Form 4/144 and a 6 July 2026 8-K with no financial-statement content). |
| What do we forecast? | Revenue growth of 19% demonstrated; a terminal operating margin of 47%; an exit multiple of 24.2x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is -11.5 percentage points. |
| What is it worth? | Twelve-month target $669.00, +61% from the struck price. Scenario-weighted expected return net of costs +60.7%. |
| Why now? | The first dated test of the thesis falls on 2 September 2026. |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| 2 September 2026 | Next scheduled results | Revenue and margin in line with, or above, the house path | A miss that moves the full-year path below the guided floor |
| 2 September 2026 | FY2027 AI semiconductor revenue guidance reduced below $100bn, OR the… | Neither leg of the condition opposite is met at this date | FY2027 AI semiconductor revenue guidance reduced below $100bn, OR the 10 GW CY2027 shipment commitment reduced/withdrawn |
| 2 September 2026 | FY2026 AI semiconductor revenue lands or is guided below $56bn | FY2026 AI semiconductor revenue lands or is guided at or above $56bn | FY2026 AI semiconductor revenue lands or is guided below $56bn |
| every 10-Q from Q3 FY26 | RPO/revenue ratio declines for two consecutive quarters | Neither leg of the condition opposite is met at this date | RPO/revenue ratio declines for two consecutive quarters |
A hyperscaler custom-XPU programme is cancelled, deferred or in-sourced during the FY2027 ramp. The 42%-of-revenue distributor / 44%-of-net-AR single counterparty means the exposure is already balance-sheet-visible; six named core AI customers concentrate programme risk. The non-cancellable RPO protects collection, not continuation: revenue collected in cash but not replaced by follow-on programmes.
Estimated probability 20%, against the 26% level at which the position would be resized. It sits within that level.
Falsifiable and fundamental — not one of them is a price condition.
On approach to the $669.00 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Not determined | Is the operating path required by today's price achievable? Not established on the evidence on file. |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | A hyperscaler custom-XPU programme is cancelled, deferred or in-sourced during the FY2027 ramp. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Met | Is there a dated event that resolves the disagreement? |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The gap between what today's price requires and what the business has demonstrated is -11.5 percentage points, and that gap — not the multiple — is the case that the security is mispriced. The most important unresolved uncertainty is whether the operating path today's price requires is achievable; the evidence does not settle it. The next evidence that should change the portfolio decision is the test dated 2 September 2026, or a daily close below $366.15, which forces an immediate review.